“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...

Dato-DXd (datopotamab deruxtecan) as a form of treatment compared to chemotherapy resulted in improved progression-free survival for patients with previously treated ...

Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new safety profiles observed. According to research presented at the European ...

Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer. Patients with previously treated, inoperable or ...

I-DXd showed a 46.2% intracranial cORR and 90.8% cDCR in ES-SCLC patients with brain metastases. Patients without prior brain radiotherapy had a higher intracranial cORR of 57.7%. The trial included ...